首页 › 癌症(所有类型) › 佛罗里达州 › Plantation
Plantation FL 癌症(所有类型)临床试验
7项针对 癌症(所有类型)的研究正在 Plantation及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
招募中3 期
- Florida Clinical Trials Group Plantation, Plantation
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- University of Miami/Sylvester Cancer Institute - Plantation, Plantation
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- University of Miami-SCCC-Plantation, Plantation
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
招募中1/2 期
- Boca Raton Clinical Research Associates, Plantation
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
招募中2 期
- BRCR Medical Center, Inc., Plantation
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
招募中1 期
- BRCR Global, Plantation
- Florida Clinical Trials Group, Plantation
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
招募中
- University of Miami Comprehensive Cancer Center at Plantation, Plantation
其他城市的 癌症(所有类型)试验
- Houston, TX121 项研究
- New York City, NY109 项研究
- Boston, MA85 项研究
- Los Angeles, CA74 项研究
- Nashville, TN65 项研究
- Philadelphia, PA59 项研究
- Washington, DC58 项研究
- Durham, NC58 项研究
- Chicago, IL51 项研究
- Atlanta, GA49 项研究
- Seattle, WA49 项研究
- Arlington, VA48 项研究
Plantation的其他研究
- 非小细胞肺癌16 项研究
- 乳腺癌14 项研究
- 狼疮7 项研究
- 肺癌7 项研究
- 转移性癌症6 项研究
- 类风湿关节炎6 项研究
- 前列腺癌5 项研究
- 银屑病关节炎5 项研究
- 结直肠癌5 项研究
- 黑色素瘤4 项研究
- 多发性骨髓瘤4 项研究
- 小细胞肺癌4 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。